Romaco Group Sells FrymaKorum?a to ProXES
The Romaco Group is selling its stake in FrymaKoruma AG (Rheinfelden, Switzerland) and FrymaKoruma GmbH (Neuenburg) to a new umbrella corporation within the Deutsche Beteiligungs AG (DBAG Frankfurt).
“During more than 10 years in affiliation with the Romaco Group, FrymaKoruma developed very well. We are pleased to offer a further growth spurt to the company in a group that specialises in process technology. Through this transaction, Romaco will focus even more on the development of its competences, especially in the pharmaceuticals market,” says Paulo Alexandre, CEO of the Romaco Group.
The companies Stephan Machinery (Hameln) and FrymaKoruma will co-operate under the new umbrella corporation ProXES. Both companies have strong brands in the area of food, pharmaceutical and health care technology and they also see an excellent complement to their previous applications and their market presence in their common future. A clear focus on process technology will ensure a stronger market position under the common umbrella corporation. Therefore, the DBAG portfolio company ProXES is acquiring the entire stake in FrymaKoruma (AG and GmbH) from the Romaco Group.
“Within the Romaco Group, we were already able to make use of significant incentives for the development of FrymaKoruma”, says Thomas Merle, director of FrymaKoruma, a little wistful about leaving the group. “We are very pleased that we can now realise previously unknown possibilities within our core business with the help of ProXES and its clear focus on process technology.”
Olaf Pehmöller, CEO of Stephan Machinery, is also happy about their new partner. “FrymaKoruma and Stephan Machinery complement each other to the benefit of both companies. For our customers, we are developing a process technology group consistent with an enterprise size which can offer more attractive proposals in better quality”, says Pehmöller, who will also act as CEO for the ProXES Group.
ProXES stands for ‘Processing and eXpert Engineering Services’, whereby the new name is at the same time a promise to our customers and thus a responsibility for the new partners. The principal shareholder is also satisfied with this focus: “With FrymaKoruma and Stephan Machinery, we have two companies which are active on the market with strong brands and an excellent reputation. The combining of the respective excellences is the logical consequence of our growth strategy which we will now implement in a focussed way”, says Dr Rolf Scheffels, member of the board of the Deutsche Beteiligungs AG.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance